Korean J Radiol.  2011 Oct;12(5):525-540. 10.3348/kjr.2011.12.5.525.

Thermal Ablation for Benign Thyroid Nodules: Radiofrequency and Laser

• Baek JH
• Lee JH
• Valcavi R
• Pacella CM
• Rhim H
• Na DG

• KMID: 1116437
• DOI: http://doi.org/10.3348/kjr.2011.12.5.525

Abstract

Although ethanol ablation has been successfully used to treat cystic thyroid nodules, this procedure is less effective when the thyroid nodules are solid. Radiofrequency (RF) ablation, a newer procedure used to treat malignant liver tumors, has been valuable in the treatment of benign thyroid nodules regardless of the extent of the solid component. This article reviews the basic physics, techniques, applications, results, and complications of thyroid RF ablation, in comparison to laser ablation.

Keyword

Radiofrequency ablation; Thyroid nodule; Ultrasonography; Ethanol ablation; Laser ablation

MeSH Terms

*Catheter Ablation/methods
Humans
*Laser Therapy/methods
Thyroid Nodule/*surgery/ultrasonography

Figure

• 

  Fig. 1 Ionic agitation and formation of frictional heat. Tissue ions are agitated by application of alternating electric current. Ionic agitation results in ion friction, which in turn causes heat production. RF = radiofrequency.

• 

  Fig. 2 Heat propagation through target tumor. Immediate tissue coagulation necrosis is achieved by frictional heat generated in vicinity of electrode, but electrode-remote tumor tissue is ablated more slowly, via conductive heat.

• 

  Fig. 3 Positions of operator and patient. Patient is placed in supine position with mild neck extension, and operator stands close to patient's head. Left hand of operator holds US probe and right hand of electrode.

• 

  Fig. 4 Three-method approach method employing electrode. Trans-isthmic approach via short axis of thyroid nodule (from medial to lateral aspect) is used in Korea. When vessels appear to be prominent on trans-isthmic approach route, lateral approach may prevent vessel injury. Cranio-caudal (longitudinal) approach, through axis of thyroid nodule, has been used in Italy for both radiofrequency ablation and percutaneous laser ablation.

• 

  Fig. 5 US image showing trans-isthmic approach. This transverse US image shows electrode in its entirety, thyroid nodule, and possible location of recurrent laryngeal nerve (small yellow circle). Electrode passes through volume of thyroid parenchyma (white circle) adequate to prevent electrode movement.

• 

  Fig. 6 US images showing danger triangle. A. Transverse image obtained before ablation, in which right thyroid nodule fills entire right thyroid gland and lies close to trachea and recurrent laryngeal nerve. B. Transverse US image taken immediately after ablation, demonstrating less-than-adequate treatment of danger triangle (white triangle), because recurrent laryngeal nerve is located in danger triangle. C. Transverse US image taken one month after ablation, showing that undertreated portion indicated by arrowheads is now apart from recurrent laryngeal nerve and trachea, thus allowing undertreated portion to be safely ablated.

• 

  Fig. 7 Sequential US images of moving shot technique showing complete ablation of nodule margins. A, B. Transverse US images showing initial placement of electrode at periphery of deep and remote portion of target nodule; ablation area was small at periphery and large in central safe area. C, D. Transverse US images showing re-location of electrode in untreated area. Electrode was continuously moved backward and in superficial direction within thyroid nodule. Entire length of electrode was always well demarcated (arrows).

• 

  Fig. 8 Transverse US images of well-ablated thyroid nodule, before (A) and 12 months after (B) radiofrequency ablation, showing size reduction, decreased echogenicity, and lack of internal vascularity.

• 

  Fig. 9 Longitudinal US images showing marginal re-growth of ablated nodule. A, B. Images taken before (A) and six months after (B) radiofrequency ablation. Shrinkage of ablated thyroid nodule is evident; however, undertreated nodule margin is observed as isoechoic area (arrowheads) in contrast to well-treated central hypoechoic portion. C. Four years after radiofrequency ablation, well-treated central hypoechoic area was reduced in size (arrowheads), but marginal untreated area showed isoechoic marginal re-growth (arrows).

• 

  Fig. 10 Transverse and longitudinal US images showing marked shrinkage of ablated nodule. Images obtained before (A, B) and 54 months after (C, D) radiofrequency ablation, showing that ablated thyroid nodule had decreased markedly in size; only small scar-like lesion remained.

• 

  Fig. 11 Microscopic changes occurring in benign thyroid nodule resected two years after laser ablation. Ablation zone is surrounded by peripheral rim of dense fibrous tissue. Destroyed area is represented by amorphous material, carbon debris, macrophages and/or multinucleated giant cells, and lymphocytes, with no thyroid cells. Viable tissue is visible at periphery (lower right corner), and is separated by fibrous tissue from ablation zone.

• 

  Fig. 12 Placement of Chiba G21 needles along cranio-caudal major nodule axis; needles are separated by 10 mm.

• 

  Fig. 13 Percutaneous laser ablation procedure using three sources. A. Longitudinal US images of needle typically placed within thyroid nodule along cranio-caudal axis. Fiber is exposed to depth about 5 mm beyond tip of needle (arrowheads). B. Highly echogenic area resulting from tissue heating and vaporization is observed during laser firing. C. Color Doppler US images obtained by laser illumination. D. Final ablation: coalescence between fibers creates single lesion matching anatomy of thyroid nodule. Laser marks are seen as anechoic spots (cavitation caused by tissue vaporization) surrounded by hyperechoic rims (charring). Coagulation zone is hypoechoic parenchyma (arrowheads) separated by rim from viable tissue.

• 

  Fig. 14 Typical three-fiber laser ablation of compact, cold, benign nodule of right thyroid lobe (volume, 25 mL). Before (A), one day after (B), one year after (C), and three years after (D) percutaneous laser ablation. Nodule shrinkage is usually associated with development of central hyperechoic area caused by tissue scarring (arrow).

Reference

1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993. 328:553–559.

2. Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: safety and imaging follow-up in 236 patients. Eur Radiol. 2008. 18:1244–1250.

3. Papini E, Guglielmi R, Bizzarri G, Pacella CM. Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules. Endocr Pract. 2004. 10:276–283.

4. Shemen LJ, Strong EW. Complications after total thyroidectomy. Otolaryngol Head Neck Surg. 1989. 101:472–475.

5. Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, et al. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid. 2007. 17:229–235.

6. Dossing H, Bennedbaek FN, Karstrup S, Hegedus L. Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation--initial experience. Radiology. 2002. 225:53–57.

7. Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology. 2004. 232:272–280.

8. Papini E, Pacella CM, Verde G. Percutaneous ethanol injection (PEI): what is its role in the treatment of benign thyroid nodules? Thyroid. 1995. 5:147–150.

9. Spiezia S, Vitale G, Di Somma C, Pio Assanti A, Ciccarelli A, Lombardi G, et al. Ultrasound-guided laser thermal ablation in the treatment of autonomous hyperfunctioning thyroid nodules and compressive nontoxic nodular goiter. Thyroid. 2003. 13:941–947.

10. Valcavi R, Frasoldati A. Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract. 2004. 10:269–275.

11. Sung JY, Baek JH, Kim YS, Jeong HJ, Kwak MS, Lee D, et al. One-step ethanol ablation of viscous cystic thyroid nodules. AJR Am J Roentgenol. 2008. 191:1730–1733.

12. Yasuda K, Ozaki O, Sugino K, Yamashita T, Toshima K, Ito K, et al. Treatment of cystic lesions of the thyroid by ethanol instillation. World J Surg. 1992. 16:958–961.

13. Zingrillo M, Torlontano M, Chiarella R, Ghiggi MR, Nirchio V, Bisceglia M, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid. 1999. 9:763–767.

14. Kim JH, Lee HK, Lee JH, Ahn IM, Choi CG. Efficacy of sonographically guided percutaneous ethanol injection for treatment of thyroid cysts versus solid thyroid nodules. AJR Am J Roentgenol. 2003. 180:1723–1726.

15. Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH. Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg. 2010. 34:1488–1493.

16. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. J Vasc Interv Radiol. 2001. 12:1135–1148.

17. Goldberg SN. Radiofrequency tumor ablation: principles and techniques. Eur J Ultrasound. 2001. 13:129–147.

18. Kang TW, Rhim H, Kim EY, Kim YS, Choi D, Lee WJ, et al. Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol. 2009. 10:34–42.

19. Lencioni R, Cioni D, Bartolozzi C. Percutaneous radiofrequency thermal ablation of liver malignancies: techniques, indications, imaging findings, and clinical results. Abdom Imaging. 2001. 26:345–360.

20. Park SH, Yoon SK, Cho JH, Oh JY, Nam KJ, Kwon HJ, et al. Radiofrequency ablation treatment for renal cell carcinoma: early clinical experience. Korean J Radiol. 2008. 9:340–347.

21. Rhim H, Goldberg SN, Dodd GD 3rd, Solbiati L, Lim HK, Tonolini M, et al. Essential techniques for successful radiofrequency thermal ablation of malignant hepatic tumors. Radiographics. 2001. 21 Spec No:S17–S35. discussion S36-19.

22. Kanauchi H, Mimura Y, Kaminishi M. Percutaneous radiofrequency ablation of the thyroid guided by ultrasonography. Eur J Surg. 2001. 167:305–307.

23. Baek JH, Jeong HJ, Kim YS, Kwak MS, Lee D. Radiofrequency Ablation for an Autonomously Functioning Thyroid Nodule. Thyroid. 2008. 18:675–676.

24. Baek JH, Kim YS, Lee D, Huh JY, Lee JH. Benign predominantly solid thyroid nodules: prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am J Roentgenol. 2010. 194:1137–1142.

25. Baek JH, Moon WJ, Kim YS, Lee JH, Lee D. Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules. World J Surg. 2009. 33:1971–1977.

26. Deandrea M, Limone P, Basso E, Mormile A, Ragazzoni F, Gamarra E, et al. US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. Ultrasound Med Biol. 2008. 34:784–791.

27. Spiezia S, Garberoglio R, Di Somma C, Deandrea M, Basso E, Limone PP, et al. Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients. J Am Geriatr Soc. 2007. 55:1478–1479.

28. Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti AP, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009. 19:219–225.

29. Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006. 16:361–367.

30. Dupuy DE, Monchik JM, Decrea C, Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery. 2001. 130:971–977.

31. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg. 2006. 244:296–304.

32. Haemmerich D, Laeseke PF. Thermal tumour ablation: devices, clinical applications and future directions. Int J Hyperthermia. 2005. 21:755–760.

33. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000. 174:323–331.

34. Baek JH, Na DG, Lee JH, Jung SL, Sung JY, Sim J, et al. Korean Society of Thyroid Radiology recommendations for radiofrequency ablation of thyroid nodules. 2009. http://thyroidimaging.kr.

35. Moon WJ, Baek JH, Jung SL, Kim DW, Kim EK, Kim JY, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol. 2011. 12:1–14.

36. Moon WJ, Jung SL, Lee JH, Na DG, Baek J-H, Lee YH, et al. Benign and malignant thyroid nodules: US differentiation--multicenter retrospective study. Radiology. 2008. 247:762–770.

37. Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics. 2003. 23:123–134. discussion 134-126.

38. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003. 226:441–451.

39. Baek JH, Kim YS, Sung JY, Choi H, Lee JH. Locoregional control of metastatic well differentiated thyroid cancer in the neck by ultrasonography-guided radiofrequency ablation. AJR Am J Roentgenol. 2011. 197:W331–W336.

40. Dachman AH, McGehee JA, Beam TE, Burris JA, Powell DA. US-guided percutaneous laser ablation of liver tissue in a chronic pig model. Radiology. 1990. 176:129–133.

41. Nikfarjam M, Muralidharan V, Malcontenti-Wilson C, Christophi C. Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy. Lasers Surg Med. 2005. 37:64–73.

42. Nolsøe CP, Torp-Pedersen S, Burcharth F, Horn T, Pedersen S, Christensen NE, et al. Interstitial hyperthermia of colorectal liver metastases with a US-guided Nd-YAG laser with a diffuser tip: a pilot clinical study. Radiology. 1993. 187:333–337.

43. Pacella CM, Rossi Z, Bizzarri G. Ultrasound-guided percutaneous laser ablation of liver tissue in a rabbit model. Eur Radiol. 1993. 3:26–32.

44. Ritz JP, Lehmann KS, Zurbuchen U, Knappe V, Schumann T, Buhr HJ, et al. Ex vivo and in vivo evaluation of laser-induced thermotherapy for nodular thyroid disease. Lasers Surg Med. 2009. 41:479–486.

45. Tranberg KG. Percutaneous ablation of liver tumours. Best Pract Res Clin Gastroenterol. 2004. 18:125–145.

46. Pacella CM, Bizzarri G, Francica G, Bianchini A, De Nuntis S, Pacella S, et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol. 2005. 16:1447–1457.

47. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract. 2010. 16:Suppl 1. 1–43.

48. Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology. 2000. 217:673–677.

49. Dossing H, Bennedbaek FN, Hegedus L. Beneficial effect of combined aspiration and interstitial laser therapy in patients with benign cystic thyroid nodules: a pilot study. Br J Radiol. 2006. 79:943–947.

50. Cakir B, Topaloglu O, Gul K, Agac T, Aydin C, Dirikoc A, et al. Effects of percutaneous laser ablation treatment in benign solitary thyroid nodules on nodule volume, thyroglobulin and anti-thyroglobulin levels, and cytopathology of nodule in 1 yr follow-up. J Endocrinol Invest. 2006. 29:876–884.

51. Dossing H, Bennedbaek FN, Hegedus L. Ultrasound-guided interstitial laser photocoagulation of an autonomous thyroid nodule: the introduction of a novel alternative. Thyroid. 2003. 13:885–888.

52. Dossing H, Bennedbaek FN, Hegedus L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules - a randomised study. Eur J Endocrinol. 2005. 152:341–345.

53. Gambelunghe G, Fatone C, Ranchelli A, Fanelli C, Lucidi P, Cavaliere A, et al. A randomized controlled trial to evaluate the efficacy of ultrasound-guided laser photocoagulation for treatment of benign thyroid nodules. J Endocrinol Invest. 2006. 29:RC23–RC26.

54. Valcavi R, Bertani A, Pesenti ML, Al Jandali Rifa' L, Frasoldati A, Formisano D, et al. Baskin HJ, Duick DS, Levine RA, editors. Laser and radiofrequency ablation procedures. Thyroid ultrasound and ultrasound-guided FNA biopsy. 2008. New York: Springer;191–218.

55. Valcavi R, Riganti F, Bertani A, Formisano D, Pacella CM. Percutaneous laser ablation of cold benign thyroid nodules: a 3-year follow-up study in 122 patients. Thyroid. 2010. 20:1253–1261.

56. Papini E, Bizzarri G, Pacella CM. Percutaneous laser ablation of benign and malignant thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2008. 15:434–439.

57. Hegedus L. Therapy: a new nonsurgical therapy option for benign thyroid nodules? Nat Rev Endocrinol. 2009. 5:476–478.